WO2013101276A3 - Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway - Google Patents

Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway Download PDF

Info

Publication number
WO2013101276A3
WO2013101276A3 PCT/US2012/031847 US2012031847W WO2013101276A3 WO 2013101276 A3 WO2013101276 A3 WO 2013101276A3 US 2012031847 W US2012031847 W US 2012031847W WO 2013101276 A3 WO2013101276 A3 WO 2013101276A3
Authority
WO
WIPO (PCT)
Prior art keywords
activation
subject
sphingolipid pathway
disease condition
diagnosis
Prior art date
Application number
PCT/US2012/031847
Other languages
French (fr)
Other versions
WO2013101276A2 (en
Inventor
Edward H. Schuchman
Original Assignee
Mount Sinai School Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School Of Medicine filed Critical Mount Sinai School Of Medicine
Publication of WO2013101276A2 publication Critical patent/WO2013101276A2/en
Publication of WO2013101276A3 publication Critical patent/WO2013101276A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides a method of detecting whether a subject has a disease condition modulated by activation of the sphingolipid pathway. This method comprises selecting a subject, detecting ceramidase level in a bodily fluid sample from the subject, and comparing the detected ceramidase level in the bodily fluid sample to a ceramidase level standard for a subject not having a disease condition modulated by activation of the sphingolipid pathway. The present invention also provides for a method of monitoring effectiveness of a therapy in a subject having a disease condition modulated by activation of the sphingolipid pathway, a method of monitoring progression of a disease condition modulated by activation of the sphingolipid pathway in a subject, and a kit with a reagent to detect ceramidase level in a bodily fluid sample and instructions for measuring ceramidase level in the sample using the reagent.
PCT/US2012/031847 2011-04-01 2012-04-02 Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway WO2013101276A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470869P 2011-04-01 2011-04-01
US61/470,869 2011-04-01

Publications (2)

Publication Number Publication Date
WO2013101276A2 WO2013101276A2 (en) 2013-07-04
WO2013101276A3 true WO2013101276A3 (en) 2013-10-03

Family

ID=48698783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/031847 WO2013101276A2 (en) 2011-04-01 2012-04-02 Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway

Country Status (1)

Country Link
WO (1) WO2013101276A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
EP3741384A1 (en) 2011-09-07 2020-11-25 Mount Sinai School Of Medicine Ceramidase and cell differentiation
CN104582770B (en) 2012-06-01 2019-01-29 西奈山伊坎医学院 Ceramide levels in the treatment and prevention of infection
PT2968479T (en) 2013-03-14 2019-08-07 Icahn School Med Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
WO2019136484A1 (en) * 2018-01-08 2019-07-11 Prevail Therapeutics, Inc. Pet imaging ligands for in vivo detection of gba1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184439A1 (en) * 2003-07-17 2007-08-09 Guilford Parry J Markers for detection of gastric cancer
US20080057590A1 (en) * 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
US20080199450A1 (en) * 2007-01-05 2008-08-21 Mount Sinai School Of Medicine Acid ceramidase and cell survival

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184439A1 (en) * 2003-07-17 2007-08-09 Guilford Parry J Markers for detection of gastric cancer
US20080057590A1 (en) * 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
US20080199450A1 (en) * 2007-01-05 2008-08-21 Mount Sinai School Of Medicine Acid ceramidase and cell survival

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HE ET AL.: "Deregulation of sphingolipid metabolism in Alzheimer's disease", NEUROBIOLOGY OF AGING, vol. 31, no. 3, 2010, pages 398 - 408 *
LIU ET AL.: "Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy", EXPERT OPINION ON THERAPEUTIC TARGETS, vol. 13, no. 12, 2009, pages 1449 - 1458 *
PARK ET AL.: "Ceramide, a crucial functional lipid, and its metabolic regulation by acid ceramidase", FOOD SCIENCE AND BIOTECHNOLOGY, vol. 19, no. 4, 2010, pages 859 - 864 *

Also Published As

Publication number Publication date
WO2013101276A2 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
WO2013113012A3 (en) Methods for profiling and quantitating cell-free rna
WO2013084002A3 (en) Method for detecting nucleosome adducts
WO2013030578A3 (en) Method for detecting nucleosomes
EA201590027A1 (en) DETECTION METHODS OF DISEASES OR CONDITIONS
TR201904386T4 (en) Method for detecting nucleosomes containing nucleotides.
WO2012012693A3 (en) Methods for detecting signatures of disease or conditions in bodily fluids
BR112013001752A2 (en) method of detecting disease or condition using phagocytic cells
MX349561B (en) Method for detecting nucleosomes containing histone variants.
WO2013039477A8 (en) Non-invasive methods of detecting target molecules
MX343327B (en) ASSAYS FOR DETECTING AUTOANTIBODIES TO ANTI-TNFa DRUGS.
EP2539712A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2008027098A3 (en) Biosensor for measurement of species in a body fluid
WO2013101276A3 (en) Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway
FR2977674B1 (en) IMPROVED METHOD OF DETECTING AND / OR QUANTIFYING AN ANALYTE PRESENT AT THE SURFACE OF A CELL
EP2857830A4 (en) Fluorescent probe for high-sensitivity pancreatic fluid detection, and method for detecting pancreatic fluid
GB201206977D0 (en) An enzyme detection device
EP2835643A4 (en) Method for detecting or quantifying analyte, kit for detecting or quantifying analyte, and test strip for lateral flow chromatography used to detect or quantify analyte
WO2014004889A3 (en) Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm
WO2011104517A3 (en) Capacitance detection in electrochemical assay
WO2014057480A3 (en) Optical fill detection
WO2013072060A3 (en) Method for the diagnosis of niemann-pick disease
WO2009149319A3 (en) Gene expression profiles associated with asthma exacerbation attacks
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
WO2012158467A3 (en) Indicators for detecting the presence of metabolic by-products from microorganisms
WO2011085057A3 (en) Methods for detecting insulin autoantibody

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12862712

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12862712

Country of ref document: EP

Kind code of ref document: A2